Objective: The current survey-based study aims to better understand expert opinion on the
most commonly prescribed anticoagulants in clinical practice, with a special focus on the …

ABSTRACT Background: Direct oral anticoagulants (DOACs) especially dabigatran, have
gain popularity for their efficacy, fixed dosing and favourable safety profile. A dabigatran …

Objectives: To provide early data regarding clinical utility of dabigatran in Al-Ain, United
Arab Emirates (UAE). Methods: This was an ethics approved retrospective cross sectional …

Background Dabigatran etexilate is an oral anticoagulant. It was added to our hospital's
formulary in 2010 for the indications of thromboprophylaxis in adult patients following total …

Introduction: Over the past few years, direct oral anticoagulants (DOACs) have been
gradually replacing warfarin. Inappropriate prescribing of DOACs in real-life practice settings …

Background Establishment of thromboembolism prevention remains a challenge despite the
widespread consensus that thromboprophylaxis safely reduces patient morbidity and …

Objective: Dabigatran etexilate is a novel oral anticoagulant with several advantages over
warfarin such as no need for routine monitoring and fewer drug interactions. This drug was …

Background: Warfarin has been the predominant treatment option for stroke prevention in AF
patients in PGH. However, it requires frequent monitoring due to its narrow therapeutic …

Background: The outpatient management of stroke prevention for patients with atrial
fibrillation has recently been published and provides insight into the benefits and risks of the …

Background Oral dabigatran was recently approved as an alternative to warfarin for
prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation …